HIM
FPRX

Hillsdale Investment Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Hillsdale Investment Management’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-56,600
Closed -$963K – 720
2020
Q4 		$963K Sell
56,600
-103,000
-65% -$1.29M 0.09% 229
2020
Q3 		$750K Buy
159,600
+37,700
+31% +$191K 0.07% 253
2020
Q2 		$744K Buy
+121,900
New +$502K 0.07% 248

Other funds holding FPRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Hillsdale Investment Management's FPRX Position: Q1 2021 in Review

Hillsdale Investment Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2021, closing a stake of 56,600 shares — an estimated $963K sold.

Hillsdale Investment Management first reported a position in FPRX in Q2 2020 and held it in 3 quarters. The position peaked at $963K in Q4 2020. 147 funds tracked by Wall St. Rank hold FPRX as of Q1 2021.

  • Hillsdale Investment Management reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
  • Hillsdale Investment Management sold 56,600 Five Prime Therapeutics, Inc. shares in Q1 2021, an estimated $963K.
  • Hillsdale Investment Management first reported a position in Five Prime Therapeutics, Inc. in Q2 2020 and held it in 3 quarters.
  • Hillsdale Investment Management's Five Prime Therapeutics, Inc. position peaked at $963K in Q4 2020.
  • 147 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2021.

Based on Hillsdale Investment Management's 13F filing for Q1 2021, filed 22 Apr 2021.